New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT02940301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining ibrutinib and nivolumab can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatment. About 18 adults will receive both drugs to see if the cancer shrinks or disappears. The goal is to improve disease control, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States